Lumiradx achieves ce mark for covid-19 antigen test on amira, its new low-cost testing system

Next-generation antigen test system built on more than eight years of research and backed by industry leading microfluidic experts the amira system includes the amira analyzer, amira sars-cov-2 ag test strips, swabs and sample preparation materials designed to provide lab-comparable performance at a lateral flow-comparable price london , june 9, 2022 /prnewswire/ -- lumiradx limited (nasdaq: lmdx), a next-generation point of care diagnostics company, today announced that it has achieved ce mark for the amira system, its new testing system that provides low-cost, highly sensitive covid-19 testing. the amira analyzer reads the included amira sars-cov-2 ag test strips and returns a result in just 15 minutes.
LMDX Ratings Summary
LMDX Quant Ranking